Arcutis Biotherapeutics Financial Statements (ARQT)
|
|
|
|
Report date
|
|
|
16.02.2021 |
22.02.2022 |
03.03.2022 |
28.02.2023 |
27.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
3.69 |
59.6 |
|
174.8 |
|
Operating Income, bln rub |
|
|
-136.6 |
-206.5 |
-206.5 |
-301.6 |
-241.1 |
|
-152.4 |
|
EBITDA, bln rub |
? |
|
-135.2 |
-206.5 |
-205.6 |
-294.6 |
-227.4 |
|
-136.4 |
|
Net profit, bln rub |
? |
|
-135.7 |
-205.9 |
-205.9 |
-321.3 |
-262.1 |
|
-164.6 |
|
|
OCF, bln rub |
? |
|
-113.0 |
-174.6 |
-174.6 |
-257.7 |
-247.1 |
|
-143.0 |
|
CAPEX, bln rub |
? |
|
0.321 |
0.995 |
0.995 |
23.3 |
0.428 |
|
0.143 |
|
FCF, bln rub |
? |
|
-113.4 |
-175.6 |
-175.6 |
-281.0 |
-247.5 |
|
-143.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
136.6 |
206.5 |
206.5 |
304.6 |
295.7 |
|
311.7 |
|
Cost of production, bln rub |
|
|
0.455 |
0.763 |
0.763 |
0.754 |
4.99 |
|
15.5 |
|
R&D, bln rub |
|
|
115.3 |
145.6 |
145.6 |
182.4 |
110.6 |
|
85.1 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
15.7 |
29.7 |
|
29.1 |
|
|
Assets, bln rub |
|
|
298.3 |
408.2 |
408.2 |
449.3 |
341.4 |
|
437.4 |
|
Net Assets, bln rub |
? |
|
270.6 |
297.7 |
297.7 |
209.6 |
88.7 |
|
156.6 |
|
Debt, bln rub |
|
|
4.96 |
77.6 |
77.6 |
202.5 |
205.9 |
|
208.2 |
|
Cash, bln rub |
|
|
284.4 |
387.1 |
387.1 |
409.6 |
271.9 |
|
330.6 |
|
Net debt, bln rub |
|
|
-279.5 |
-309.5 |
-309.5 |
-207.0 |
-65.9 |
|
-122.4 |
|
|
Ordinary share price, rub |
|
|
28.1 |
20.7 |
20.7 |
14.8 |
3.23 |
|
2.21 |
|
Number of ordinary shares, mln |
|
|
35.7 |
49.4 |
49.4 |
55.0 |
69.3 |
|
124.3 |
|
|
Market cap, bln rub |
|
|
1 003 |
1 025 |
1 025 |
814 |
224 |
|
275 |
|
EV, bln rub |
? |
|
724 |
715 |
715 |
607 |
158 |
|
152 |
|
Book value, bln rub |
|
|
271 |
298 |
298 |
202 |
82 |
|
147 |
|
|
EPS, rub |
? |
|
-3.80 |
-4.17 |
-4.17 |
-5.84 |
-3.78 |
|
-1.32 |
|
FCF/share, rub |
|
|
-3.18 |
-3.55 |
-3.55 |
-5.11 |
-3.57 |
|
-1.15 |
|
BV/share, rub |
|
|
7.59 |
6.03 |
6.03 |
3.68 |
1.19 |
|
1.18 |
|
|
EBITDA margin, % |
? |
|
|
|
|
-7 991% |
-381.6% |
|
-78.1% |
|
Net margin, % |
? |
|
|
|
|
-8 716% |
-439.8% |
|
-94.2% |
|
FCF yield, % |
? |
|
-11.3% |
-17.1% |
-17.1% |
-34.5% |
-110.6% |
|
-52.1% |
|
ROE, % |
? |
|
-50.1% |
-69.2% |
-69.2% |
-153.3% |
-295.6% |
|
-105.1% |
|
ROA, % |
? |
|
-45.5% |
-50.4% |
-50.4% |
-71.5% |
-76.8% |
|
-37.6% |
|
|
P/E |
? |
|
-7.40 |
-4.98 |
-4.98 |
-2.54 |
-0.85 |
|
-1.67 |
|
P/FCF |
|
|
-8.85 |
-5.83 |
-5.83 |
-2.90 |
-0.90 |
|
-1.92 |
|
P/S |
? |
|
|
|
|
221.0 |
3.76 |
|
1.57 |
|
P/BV |
? |
|
3.71 |
3.44 |
3.44 |
4.02 |
2.72 |
|
1.87 |
|
EV/EBITDA |
? |
|
-5.35 |
-3.46 |
-3.48 |
-2.06 |
-0.69 |
|
-1.12 |
|
Debt/EBITDA |
|
|
2.07 |
1.50 |
1.51 |
0.70 |
0.29 |
|
0.90 |
|
|
R&D/CAPEX, % |
|
|
35 921% |
14 629% |
14 629% |
783.6% |
25 835% |
|
59 497% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
631.7% |
0.72% |
|
0.08% |
|
| Arcutis Biotherapeutics shareholders |
